🔗 Share this article

Ministers and senior MPs have raised concerns that the United Kingdom's negotiated accords with Washington are "fundamentally unstable." This stems from revelations that a much-touted deal on pharmaceutical tariffs, which promises zero tariffs in exchange for the NHS facing higher prices, lacks any detailed agreement beyond limited headline terms published in government press releases.

A Deal Without Detail

The arrangement concerning medicines, described as a "significant" achievement, exists as an "statement of intent" without a signed legal text. It has been highlighted that the press releases from the UK and US governments present the deal in markedly contrasting terms. The British version emphasizes securing "duty-free access" as a unique achievement, while the American announcement dwells on the expectation for the NHS to pay higher prices for new medications.

"There is a serious risk that the UK government has promised concessions to increase medicine costs in return for nothing more than a verbal promise from President Trump," commented David Henig, a trade policy analyst. "We know he has a tendency for not honouring his word."

Broader Instability and a Paused Tech Deal

Worries have been heightened by Washington's action to put on ice the major technology agreement, which was previously called "a transformative pact" in the bilateral relationship. The US claimed a lack of progress from the UK on lowering trade barriers as the reason for the pause.

Additionally, concessions secured for British farmers as part of an May trade agreement have still not been formally approved by the US, despite a imminent January deadline. "Our understanding is that the US has not finalized the agreed beef export quotas," said Tom Bradshaw of the National Farmers' Union.

Uncertainty Among Officials

Privately, ministers have voiced worries that the government's deals with Washington are flimsy and unreliable. One minister was quoted as stating the series of agreements as "resting on shaky ground," while another described the situation as the "new normal" in the transatlantic relationship, marked by "greater risk and fluctuation."

Layla Moran, a senior MP on the health committee, stated: "The only thing more surprising than the administration's tactics is the UK government's optimistic assumption that his administration is a good faith actor. The NHS is of vital importance."

A Mixed Picture of Success and Setback

Officials have sought to reduce the possibility of the US withdrawing from the pharmaceuticals deal. One source indicated the US pharmaceutical industry itself had been pushing for the agreement, wanting clarity on imports and pricing, making it of tangible value than the paused tech deal.

Officials admit that instability is part and parcel of dealing with the current US leadership. However, they contend that the UK has secured concrete outcomes for businesses, such as reduced duties on automobiles compared to other nations. "Securing 25% steel tariffs, which is lower than the rate for the rest of the world, is a solid gain," one official said.

However, problems have arisen in enacting the broader trade deal. Promised quotas on beef exports have yet to be finalized, and the assurance to "reduce steel tariffs to zero" has remains unmet, with tariffs staying at 25%.

Looking ahead, the two sides have agreed to resume talks on the paused tech prosperity deal in January, following what were described as "productive" meetings between UK and US officials in Washington.